CSIMarket
 
Baudax Bio Inc   (BXRX)
Other Ticker:  
 
 
Price: $0.0203 $0.00 -11.739%
Day's High: $0.0239 Week Perf: -7.73 %
Day's Low: $ 0.02 30 Day Perf: -23.68 %
Volume (M): 460 52 Wk High: $ 3.47
Volume (M$): $ 9 52 Wk Avg: $0.53
Open: $0.02 52 Wk Low: $0.01



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 8
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -7
 Cash Flow (TTM) (Millions $) -4
 Capital Exp. (TTM) (Millions $) 0

Baudax Bio Inc
Baudax Bio Inc is a pharmaceutical company that focuses on developing and commercializing innovative pharmaceutical products for acute care settings. The company is committed to addressing important unmet medical needs and improving patient outcomes. Baudax Bio's flagship product is Anjeso, which is a non-opioid, long-acting NSAID (non-steroidal anti-inflammatory drug) for the management of moderate to severe pain. The company's mission is to advance the future of acute care therapeutics through the development of novel products that provide meaningful clinical benefit to patients and healthcare providers.


   Company Address: 490 Lapp Road Malvern 19355 PA
   Company Phone Number: 395-2440   Stock Exchange / Ticker: NASDAQ BXRX
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Baudax Bio Inc

Baudax Bio Inc's Revenue Shows Steady Comparison to Previous Year During July-September 2023 Period



Baudax Bio Inc, a pharmaceutical company listed on the NASDAQ, recently released its financial results for the July to September 2023 period. The company demonstrated significant improvements in its loss per share and earnings per share compared to the previous year and the previous quarter. Despite revenue remaining unchanged, Baudax Bio Inc reported a substantial decrease in its net shortfall. This article aims to outline the facts and interpret these financial results.
1. Improving Financial Performance:
For the July to September 2023 period, Baudax Bio Inc managed to decrease its loss per share from $-2.47 to $-0.30 when compared to the same quarter last year, showcasing a remarkable improvement. Moreover, earnings per share saw significant growth from $-1.51 in the previous quarter to the current quarter.

Baudax Bio Inc

Baudax Bio Inc shines with a series of remarkable achievements throughout Q2 2023

Baudax Bio Inc, a pharmaceutical company, recently released its financial results for the second quarter of 2023. The company reported a shortfall per share of $-1.51 compared to $-1.05 in the same period last year. Additionally, the earnings per share (EPS) fell from $4.91 in the preceding reporting period. Though these figures may seem concerning, it is essential to analyze the larger context of the company's performance.
One key point to note is that Baudax Bio Inc experienced no change in revenue, with $0.00 million reported for the second quarter of 2023. This is consistent with the revenue figures from the previous year, which also stood at $0.00 million. While flat revenue may not indicate significant growth, it is worth monitoring how the company plans to address this stagnation in future quarters.

Baudax Bio Inc

Baudax Bio Inc Surprises Investors with Stunning Turnaround, Reports EPS of $4.91 per Share in Q1 2023

Baudax Bio Inc, a pharmaceutical company that operates in the pain management sector, recently announced impressive financial results for the period closing March 31, 2023. The company surprised investors and analysts alike by posting earnings per share (EPS) of $4.91 per share, a stark improvement from the negative EPS of $-3.17 from the previous year, indicating a significant turnaround in their financial fortunes.
Furthermore, Baudax Bio Inc's revenues remained somewhat constant, standing at $0.00 million, mirroring the previous year's figure of $0.42 million. Although there was no significant improvement on the revenue side, it was a positive indicator that the company had managed to maintain its position.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com